42 results on '"Sandecka V"'
Search Results
2. Fludarabine with high-dose cytarabine and sequential reduced-intensity conditioning with allogeneic stem cell transplantation in 24 patients with advanced lymphoid malignancies: efficacy and outcomes: P981
3. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience
4. Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens: B228
5. High HGF Levels are Associated with Response to Bortezomib: B226
6. Better Efficacy/Toxicity Ratio of Velcade-Based Regimens: A251
7. High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment: A185
8. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients
9. Scleredema associated with multiple myeloma or MGUS: treatment report of four cases
10. Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories
11. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
12. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results
13. A251 Better Efficacy/Toxicity Ratio of Velcade-Based Regimens
14. A185 High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment
15. B228 Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens
16. B226 High HGF Levels are Associated with Response to Bortezomib
17. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
18. Lenalidomide-based regimen proved effective in multisystem Langerhans cell histiocytosis: case report
19. Lenalidomide as a new treatment option for Castleman disease: first experience
20. EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELOMA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC
21. Velcade with possible benefit over the autologous retransplantation in relapsing multiple myeloma
22. GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
23. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.
24. Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.
25. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
26. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
27. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
28. CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity.
29. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
30. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
31. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant.
32. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
33. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
34. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
35. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
36. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
37. Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.
38. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
39. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
40. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.
41. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
42. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.